UPDATE 1-Novartis gene therapy would be cost effective up to $900,000 -U.S. group
February 22, 2019 at 15:08 PM EST
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth a price of $310,000 to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.
